FT Options’s ImmunityBio IBRX Stock Holding History

FT Options’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-2,000	Closed	-$1K	–	313
2015 Q4	$1K	Buy	+2,000	New	+$29.7K	﹤0.01%	201

Other funds holding IBRX

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

FT Options's IBRX Position: Q1 2016 in Review

FT Options sold out of ImmunityBio (IBRX) in Q1 2016, closing a stake of 14,471 shares — an estimated $251K sold.

FT Options first reported a position in IBRX in Q4 2015 and held it in 1 quarter. The position peaked at $251K in Q4 2015. 62 funds tracked by Wall St. Rank hold IBRX as of Q1 2016.

FT Options reported no remaining ImmunityBio position as of Q1 2016 after selling out during the quarter.
FT Options sold 14,471 ImmunityBio shares in Q1 2016, an estimated $251K.
FT Options first reported a position in ImmunityBio in Q4 2015 and held it in 1 quarter.
FT Options's ImmunityBio position peaked at $251K in Q4 2015.
62 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2016.

Based on FT Options's 13F filing for Q1 2016, filed 9 May 2016.